Acetylcholinesterase and Its Inhibition in Alzheimer Disease
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Until recently, the only established function of acetylcholinesterase (AChE) was the termination of cholinergic neurotransmission. Therefore, the use of AChE inhibitors to treat symptoms caused by cholinergic imbalances in Alzheimer disease (AD) represented a rational approach. However, it is now clear that AChE and the cholinergic system may have broader effects in AD. Of particular interest may be signal transduction pathways mediated through cholinergic receptors that promote nonamyloidogenic amyloid precursor protein processing and decrease tau phosphorylation, and the role of AChE in the aggregation of beta-amyloid (Abeta) peptide. In addition, the neuronal and nonneuronal cholinergic systems have important roles in the modulation of regional cerebral blood flow. These findings may modify the overly simplistic cholinergic hypothesis in AD that is limited to symptomatic treatment and ignores the potential of cholinergic therapies as disease-modifying agents. Chronic increases in AChE activity may exacerbate neurodegenerative processes, make clinically relevant levels of AChE inhibition more difficult to achieve, and cause the therapeutic value of cholinesterase inhibitors (ChE-Is) to be limited and temporary. Rapidly reversible ChE-Is appear to increase AChE activity over the longer term whereas, remarkably, irreversible or very slowly reversible ChE-Is do not seem to have this effect. If such differences between ChE-Is are shown to have clinical correlates, this may prompt reconsideration of the rationale and expectations of some agents in the long-term management of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acute stress facilitates long-lasting changes in cholinergic gene expression
Kaufer, D., Friedman, A., Seidman, S., & Soreq, H. (1998) · Nature · doi:10.1038/30741 · Cited by 588
Donepezil in vascular dementia: A randomized, placebo-controlled study
Wilkinson, D., Doody, R., Helme, R., Taubman, K., Mintzer, J., Kertesz, A., Pratt, R. D., & the Donepezil 308 Study Group* (2003) · Neurology · doi:10.1212/01.wnl.0000078943.50032.fc · Cited by 392
Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
Grossberg, G. T. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00059-6 · Cited by 384 · cited 2×
“The administration of rivastigmine involves twice-daily dosing with, or shortly after, meals and a more flexible titration scheme that some doctors initially find complex and that, if performed too rapidly, may result in an increased incidence of centrally mediated cholinergic side effects such as nausea and vomiting.…”
BackgroundDoody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362
Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J. (2000) · European Neurology · doi:10.1159/000008243 · Cited by 332
Arendt, T., Brückner, M. K., Lange, M., & Bigl, V. (1992) · Neurochemistry International · doi:10.1016/0197-0186(92)90189-x · Cited by 314
Cited by
The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease
Schliebs, R., & Arendt, T. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0579-2 · Cited by 530
Chigurupati, S., Selvaraj, M., Mani, V., Selvarajan, K. K., Mohammad, J. I., Kaveti, B., Bera, H., Palanimuthu, V. R., Teh, L. K., & Salleh, M. Z. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.05.002 · Cited by 82
Zeatin supplement improves scopolamine-induced memory impairment in mice
KIM, M. J., CHOI, S. J., LIM, S.-T., KIM, H. K., KIM, Y. J., YOON, H.-G., & SHIN, D.-H. (2008) · Bioscience, Biotechnology, and Biochemistry · doi:10.1271/bbb.70480 · Cited by 47
Jeong, S. Y., Suh, C. H., Lim, J.-S., Shim, W. H., Heo, H., Choi, Y., Kim, H. S., Kim, S. J., & Lee, J.-H. (2025) · Neurology · doi:10.1212/wnl.0000000000213483 · Cited by 36
Protein-Protein Interactions and Aggregation Inhibitors in Alzheimer’s Disease
Ganeshpurkar, A., Swetha, R., Kumar, D., Gangaram, G. P., Singh, R., Gutti, G., Jana, S., Kumar, D., Kumar, A., & Singh, S. K. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190304153353 · Cited by 30
Metadata
- Authors
- Lane, R. M., Kivipelto, M., & Greig, N. H.
- Venue
- Clinical Neuropharmacology
- Published
- 2004-05
- Volume
- 27
- Issue
- 3
- Pages
- 141-149
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W1968126540
- Cited by
- 149
- References
- 6
- FWCI
- 5.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Acetylcholinesterase and Its Inhibition in Alzheimer Disease. https://app.cochat.ai/papers/10.1097/00002826-200405000-00011
- The paper
- Lane, R. M., Kivipelto, M., & Greig, N. H. (2004). Acetylcholinesterase and Its Inhibition in Alzheimer Disease. Clinical Neuropharmacology. https://doi.org/10.1097/00002826-200405000-00011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.